Last €1.81 EUR
Change Today -0.068 / -3.62%
Volume 0.0
PBD On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
Tel Aviv
As of 12:59 PM 10/2/14 All times are local (Market data is delayed by at least 15 minutes).

protalix biotherapeutics inc (PBD) Snapshot

Open
€1.86
Previous Close
€1.88
Day High
€1.88
Day Low
€1.80
52 Week High
03/7/14 - €3.77
52 Week Low
08/25/14 - €1.75
Market Cap
169.3M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
93.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROTALIX BIOTHERAPEUTICS INC (PBD)

protalix biotherapeutics inc (PBD) Related Businessweek News

No Related Businessweek News Found

protalix biotherapeutics inc (PBD) Details

Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company’s product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-112, an orally administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant glucocerebrosidase enzyme produced and encapsulated within carrot cells; and PRX-106, an oral antiTNF, a plant cell expressed recombinant fusion protein combined of the binding domain of the human TNF receptor and an antibody portion, which is being developed for the treatment of certain immune and inflammatory diseases, such as rheumatoid arthritis, colitis, Crohn’s disease, psoriasis, and other autoimmune and inflammatory disorders. Its product pipeline also comprises PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1 under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and PRX-107, a proprietary plant cell recombinant human Alpha1-antitrypsin and others. The company has a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. to develop and manufacture two proteins using its ProCellEx protein expression system. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Carmiel, Israel.

260 Employees
Last Reported Date: 03/13/14
Founded in 1993

protalix biotherapeutics inc (PBD) Top Compensated Officers

Chief Executive Officer, President, Executive...
Total Annual Compensation: $577.7K
Founder, Executive Vice President of Research...
Total Annual Compensation: $422.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $402.1K
Chief Operating Officer
Total Annual Compensation: $251.7K
Senior Vice President of Product Development
Total Annual Compensation: $361.5K
Compensation as of Fiscal Year 2013.

protalix biotherapeutics inc (PBD) Key Developments

Protalix BioTherapeutics, Inc. Announces Management Changes

Protalix BioTherapeutics, Inc. announced that its Board of Directors has appointed Moshe Manor as its new President and Chief Executive Officer. Mr. Manor will assume office on November 2, 2014, when Dr. Aviezer will retire. He brings extensive knowledge and vast senior experience, both in the generic and the innovative pharmaceutical world, from his years as Executive Vice President at Teva Pharmaceutical Industries. Most recently, Manor served as President, Teva Asia & Pacific where he led the strategy and development of a high growth region for Teva.

Protalix BioTherapeutics, Inc. - Special Call

To discuss the recent approval of ELELYSO for pediatric patients and also provide an update on the additional ongoing clinical programs, PRX-112 and PRX-102

Pfizer Inc. and Protalix BioTherapeutics, Inc. Announce FDA Approval of Pediatric Indication for ELELYSO (Taliglucerase Alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease

Pfizer Inc. and Protalix BioTherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved ELELYSO(TM) (taliglucerase alfa) for injection for pediatric patients. ELELYSO is therefore now indicated for long-term enzyme replacement therapy (ERT) for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease. The safety and efficacy of ELELYSO were assessed in fourteen pediatric patients with Type 1 Gaucher disease in two clinical trials. The first trial consisted of nine patients in a 12-month, multi-center, double-blind, randomized study in treatment-naïve patients aged two to 13 years. At the end of the 12-month study, therapeutic efficacy of ELELYSO was demonstrated, as measured by a decrease in spleen and liver volume and an increase in platelet count. A second trial consisted of 5 pediatric patients aged 6 to 16 years who were switched from imiglucerase to ELELYSO. The trial was a 9-month, multi-center, open-label, single-arm study in patients who had been receiving treatment with imiglucerase at dosages ranging from 9.5 units/kg to 60 units/kg every other week for a minimum of 2 years. ELELYSO was administered for 9 months at the same dose as each patient's previous imiglucerase dose. If needed, adjustment of dosage was allowed during the study in order to maintain stability of clinical parameters. Mean spleen and liver volume, platelet count and hemoglobin value remained stable through 9 months of ELELYSO treatment. The recommended dosage of ELELSYO for treatment-naïve adult and pediatric patients four years of age and older is 60 units per kg of body weight administered every other week as a 60 to 120 minute intravenous infusion. Patients previously treated on a stable dosage of imiglucerase are recommended to begin treatment with ELELYSO at that same dosage when they switch from imiglucerase to ELELYSO. Dosage adjustments can be made based on achievement and maintenance of each patient's therapeutic goals.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PBD:GR €1.81 EUR -0.068

PBD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PBD.
View Industry Companies
 

Industry Analysis

PBD

Industry Average

Valuation PBD Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTALIX BIOTHERAPEUTICS INC, please visit www.protalix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.